var data={"title":"Stenotrophomonas maltophilia","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Stenotrophomonas maltophilia</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/contributors\" class=\"contributor contributor_credentials\">Sarah S Lewis, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/contributors\" class=\"contributor contributor_credentials\">Aimee Zaas, MD, MHS</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/contributors\" class=\"contributor contributor_credentials\">Allyson Bloom, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H47084643\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Stenotrophomonas </em>(<em>Xanthomonas</em>) <em>maltophilia</em> is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/1-4\" class=\"abstract_t\">1-4</a>], particularly among hospitalized patients. <em>S. maltophilia</em> infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals. </p><p>The clinical features and management of <em>S. maltophilia</em> infections are discussed here. The general approach to gram-negative bacillary bacteremia, catheter-associated bloodstream infections, and hospital-acquired pneumonia are discussed elsewhere. (See <a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults\" class=\"medical medical_review\">&quot;Gram-negative bacillary bacteremia in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">&quot;Treatment of intravascular catheter-related infections&quot;</a> and <a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Treatment of hospital-acquired and ventilator-associated pneumonia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H47084650\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> is a ubiquitous, aerobic, non-fermentative, gram-negative bacillus that is closely related to the <em>Pseudomonas</em> species [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/5\" class=\"abstract_t\">5</a>]. The name signifies &quot;a unit feeding on few substrates,&quot; based on the Greek roots stenos (narrow), trophos (one who feeds), and monas (a unit). <em>Maltophilia</em> means &quot;affinity for malt,&quot; based on the Greek roots maltum (malt) and philia (affinity).</p><p><em>S. maltophilia</em> is an obligate aerobe that grows well on commonly used laboratory media, including blood and MacConkey agars. It is lactose nonfermenting, oxidase-negative, and catalase-positive and can be reliably identified in the laboratory using standard biochemical tests. In addition, it is accurately identified by commercially available automated identification systems [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/4\" class=\"abstract_t\">4</a>]. Matrix-assisted laser <span class=\"nowrap\">desorption/ionization</span> (MALDI) identification of <em>Stenotrophomonas </em>is not yet standard for many microbiology laboratories. </p><p><em>S. maltophilia</em> was first isolated in 1943 and, at the time, was named <em>Bacterium bookeri</em>. It was later classified within the genus <em>Pseudomonas</em>, then <em>Xanthomonas</em>, and then finally <em>Stenotrophomonas</em> in 1993 [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/4,6,7\" class=\"abstract_t\">4,6,7</a>]. <em>S. maltophilia</em> is the only species of <em>Stenotrophomonas</em> known to infect humans [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7\" class=\"abstract_t\">7</a>], whereas its closest genetic relatives are plant pathogens [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7,8\" class=\"abstract_t\">7,8</a>]. It is frequently isolated from soil, water, animals, plant matter, and hospital equipment [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/4,9-21\" class=\"abstract_t\">4,9-21</a>]. <em>S. maltophilia</em> has inherent ability to adhere to foreign materials and form a biofilm, rendering protection from host defenses as well as antimicrobial agents [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/18,19,22-26\" class=\"abstract_t\">18,19,22-26</a>]. Factors contributing to this behavior include its positively charged surface and fimbrial adhesions [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7,22-24,26-28\" class=\"abstract_t\">7,22-24,26-28</a>]. </p><p>In addition, <em>S. maltophilia</em> has intrinsic or acquired resistance mechanisms to several antibiotic classes. Resistance to beta-lactams is conferred by two inducible beta-lactamases, a zinc-containing penicillinase (L1) and a cephalosporinase (L2) [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/21,29-32\" class=\"abstract_t\">21,29-32</a>]. An aminoglycoside acetyl-transferase confers resistance to aminoglycoside antibiotics [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/33-39\" class=\"abstract_t\">33-39</a>]. Temperature-dependent changes in the outer membrane lipopolysaccharide (LPS) structure have been associated with added resistance to aminoglycoside antibiotics [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/18,40-43\" class=\"abstract_t\">18,40-43</a>]. In addition, many strains of <em>S. maltophilia</em> possess efflux pumps, which confer further resistance to multiple antibacterial classes [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/39,44-47\" class=\"abstract_t\">39,44-47</a>]. (See <a href=\"#H3886429437\" class=\"local\">'Efficacy of antibiotic options'</a> below.)</p><p>There are uncertainties regarding the optimal approach to in vitro susceptibility testing given discrepancies between results of various methods [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/48-51\" class=\"abstract_t\">48-51</a>]. The US Clinical and Laboratory Standards Institute (CSLI) has published disc-diffusion minimal inhibitory concentration (MIC) breakpoints for <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a>, and <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> and broth dilution MIC breakpoints for ticarcillin-clavulanic acid, <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, minocycline, levofloxacin, and <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a> [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/18,49,52,53\" class=\"abstract_t\">18,49,52,53</a>]. Etest may be used for evaluation of ceftazidime, minocycline, and chloramphenicol susceptibility. There are no MIC interpretive criteria for <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> or <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, although susceptibility to tigecycline is assumed using interpretive criteria for Enterobacteriaceae<em> </em>[<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/54\" class=\"abstract_t\">54</a>]. In contrast, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) has only published breakpoint criteria for trimethoprim-sulfamethoxazole [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H47084657\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reported incidence of <em>S. maltophilia</em> infections ranges from 7.1 to 37.7 cases per 10,000 discharges [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/4,39,48,56\" class=\"abstract_t\">4,39,48,56</a>]. The incidence seems to be increasing as the population of patients at risk increases [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/1,4,49,57-59\" class=\"abstract_t\">1,4,49,57-59</a>]. This increase is probably due to advances in the treatment of malignancy, increased use of invasive devices, and widespread use of broad-spectrum antibiotics. </p><p>Risk factors associated with <em>S. maltophilia</em> infection include admission to an intensive care unit (ICU), HIV infection, malignancy, cystic fibrosis, neutropenia, mechanical ventilation, central venous catheters, recent surgery, trauma, and previous therapy with broad-spectrum antibiotics [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/1,2,4,20,21,48,57,58,60\" class=\"abstract_t\">1,2,4,20,21,48,57,58,60</a>]. <em>S. maltophilia</em> infections are typically hospital-acquired; even in community-acquired infections, most affected individuals have significant healthcare exposure or predisposing comorbidities (eg, prior trauma, immunocompromising condition, indwelling devices) [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/61\" class=\"abstract_t\">61</a>].</p><p>A number of outbreaks of <em>S. maltophilia</em> have been described involving adult ICU patients [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/62-64\" class=\"abstract_t\">62-64</a>], hematologic malignancy and bone marrow transplant recipients [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/65,66\" class=\"abstract_t\">65,66</a>], hemodialysis patients [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/67\" class=\"abstract_t\">67</a>], and neonates [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Patient exposure to contaminated tap water has been the suspected etiology in many outbreaks [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/64,66,68\" class=\"abstract_t\">64,66,68</a>]. In addition, a number of outbreaks and pseudo-outbreaks have been associated with failures in endoscope reprocessing [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/70-74\" class=\"abstract_t\">70-74</a>].</p><p class=\"headingAnchor\" id=\"H2963639\"><span class=\"h1\">DISEASE ASSOCIATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pneumonia and bacteremia are the most common manifestations of infection [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/2,4,39,49,50,75-78\" class=\"abstract_t\">2,4,39,49,50,75-78</a>]. </p><p class=\"headingAnchor\" id=\"H4108514156\"><span class=\"h2\">Pulmonary infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> pneumonia is usually hospital-acquired and most frequently occurs in mechanically ventilated patients. Compared with pulmonary colonization, infection is associated with underlying immunosuppression [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/79\" class=\"abstract_t\">79</a>]. Clinical and radiographic findings are generally similar to those seen with other infectious causes of hospital-acquired pneumonia. However, in patients with hematologic malignancies, a syndrome of rapidly progressive and frequently fatal hemorrhagic pneumonia associated with <em>S. maltophilia</em> infection has been increasingly reported [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/9,80,81\" class=\"abstract_t\">9,80,81</a>].</p><p><em>S. maltophilia</em> is a recognized pathogen for cystic fibrosis patients in the United States, with overall prevalence rates similar to those of nontuberculous mycobacteria [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/82\" class=\"abstract_t\">82</a>]. <em>S. maltophilia</em> infection correlates with decline in lung function in adult and pediatric cystic fibrosis patients; however, causality has not been determined [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/83,84\" class=\"abstract_t\">83,84</a>]. (See <a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection#H7493970\" class=\"medical medical_review\">&quot;Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection&quot;, section on 'Other pathogens'</a>.)</p><p class=\"headingAnchor\" id=\"H1196897287\"><span class=\"h2\">Bacteremia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of <em>S. maltophilia</em> bacteremia are associated with indwelling catheters [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/3,85\" class=\"abstract_t\">3,85</a>]. As an example, in a study of 207 oncology patients with a central venous catheter and <em>S. maltophilia</em> bloodstream infection, 73 percent of infections were deemed to be catheter-related, 22 percent were secondary (mainly from a pulmonary source), and 5 percent were thought to be primary and non-catheter related [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/85\" class=\"abstract_t\">85</a>]. Many catheter-related <em>S. maltophilia</em> bloodstream infections are polymicrobial. Relapse of catheter-associated bacteremia, even up to 200 days after treatment of the initial infection, is also described and has been associated with prolonged neutropenia and catheter retention [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/86\" class=\"abstract_t\">86</a>]. </p><p>Other sources of bacteremia include the gastrointestinal tract or severe mucositis in patients with profound neutropenia [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/85,87\" class=\"abstract_t\">85,87</a>] </p><p class=\"headingAnchor\" id=\"H131225346\"><span class=\"h2\">Other manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Less common manifestations of <em>S. maltophilia</em> infections include endocarditis, mastoiditis, peritonitis, meningitis,<sup> </sup>soft tissue infection, wound infection, urinary tract infection, and ocular infection [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/2,4,39,49,50,76-78,88\" class=\"abstract_t\">2,4,39,49,50,76-78,88</a>]. <em>Stenotrophomonas</em> can also cause cutaneous manifestations, which may reflect metastatic infection or local infiltration [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/89,90\" class=\"abstract_t\">89,90</a>]. Reported skin manifestations include cellulitis, infected ulcers, and ecthyma gangrenosum.</p><p class=\"headingAnchor\" id=\"H2258015482\"><span class=\"h1\">DIAGNOSIS OF INFECTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> can be readily identified on culture of relevant clinical specimens. Growth of <em>S. maltophilia</em> from normally sterile sites (such as blood or peritoneal fluid) should be interpreted to represent true infection. However, since <em>S. maltophilia</em> can adhere to the mucosal surfaces of the upper airway and large bronchi and may colonize these areas without causing infection, it is important to differentiate colonization from true infection due to <em>S. maltophilia</em>, particularly from respiratory isolates. </p><p>In patients with clinical evidence of pneumonia (eg, new pulmonary infiltrate, decreased oxygenation, and fever <span class=\"nowrap\">and/or</span> leukocytosis), cultures growing <em>S. maltophilia</em> (with or without other concurrent respiratory pathogens) from respiratory sites should be interpreted to be consistent with true infection.</p><p>In the absence of consolidation on chest radiography and other clinical signs of pulmonary infection, a positive respiratory tract isolate of <em>Stenotrophomonas</em> probably represents colonization rather than invasive disease. In a retrospective review of 92 patients presenting with acute respiratory symptoms and subsequently found to have respiratory cultures positive for <em>S. maltophilia</em>, there was no measurable impact of antibiotic therapy in the absence of chest radiograph consolidation [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/91\" class=\"abstract_t\">91</a>]. </p><p>Additionally, clinicians must use caution when interpreting culture data obtained from non-sterile sites such as indwelling urinary catheters, surgical drains, and vascular catheter hubs, given the organism's propensity to colonize foreign materials. In these situations, the assessment for clinical evidence of infection (eg, fever, leukocytosis, localized pain) is critical. In the absence of bacteremia or evidence of infection in other sterile sites (such as pleural fluid, peritoneal fluid), such culture findings may be presumed to reflect colonization rather than infection.</p><p class=\"headingAnchor\" id=\"H1439026460\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H1646623428\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> infections should be treated with antibiotics promptly given that delay in appropriate treatment can contribute to significant mortality. Whether isolation of <em>S. maltophilia</em> from a clinical specimen represents true infection rather than colonization warrants careful assessment, as colonization should not be treated and inappropriate antibiotic use contributes to added adverse effects and selection for resistant organisms. Distinguishing between infection and colonization is discussed elsewhere. (See <a href=\"#H2258015482\" class=\"local\">'Diagnosis of infection'</a> above.) </p><p>In cases in which the distinction between infection and colonization is uncertain (eg, in a patient who is known to have airway colonization with <em>S. maltophilia</em> and subsequently develops clinical evidence of pneumonia), we recommend initiation of treatment for <em>S. maltophilia</em> until additional clinical information is available. After 48 to 72 hours, we re-evaluate the need for continued <em>S. maltophilia</em> therapy in such patients. We do not typically include <em>S. maltophilia</em> coverage in empiric treatment of pneumonia or for sepsis in critically ill patients or immunocompromised patients without prior evidence of <em>S. maltophilia </em>colonization.</p><p class=\"headingAnchor\" id=\"H3886429437\"><span class=\"h2\">Efficacy of antibiotic options</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> is a multidrug-resistant organism, so antibiotic options are limited and clinical data are limited regarding optimal therapy. <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">Trimethoprim-sulfamethoxazole</a> (TMP-SMX) is the treatment of choice as it has the most reliable in vitro activity against <em>S. maltophilia</em> [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/92-94\" class=\"abstract_t\">92-94</a>]. As an example, in a surveillance study of gram-negative organisms isolated from patients hospitalized with pneumonia between 2009 and 2012, susceptibility to TMP-SMX was documented for 96 percent of the 302 <em>S. maltophilia</em> isolates from United States hospitals and 98 percent of the 192 isolates from European hospitals [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/92\" class=\"abstract_t\">92</a>]. Additionally, observational studies and case series report favorable clinical outcomes when TMP-SMX is used [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/57,95\" class=\"abstract_t\">57,95</a>]. However, some patients are unable to tolerate TMP-SMX due to hypersensitivity reaction, drug toxicity, or other adverse reaction. Furthermore, in vitro resistance to TMP-SMX among <em>S. maltophilia</em> isolates has been increasingly reported, particularly in patients with cystic fibrosis [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/49,75,96,97\" class=\"abstract_t\">49,75,96,97</a>]. </p><p>Fluoroquinolones, in particular <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a>, are potential alternatives to TMP-SMX [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/93\" class=\"abstract_t\">93</a>]. In the surveillance study discussed above, 75 to 84 percent of <em>S. maltophilia</em> pulmonary isolates were susceptible to levofloxacin [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/92\" class=\"abstract_t\">92</a>]. Additionally, small retrospective studies have suggested similar clinical outcomes (microbiologic cure, clinical success, and short-term mortality rates) in <em>S. maltophilia</em> infection with fluoroquinolone versus TMP-SMX monotherapy [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/95,98\" class=\"abstract_t\">95,98</a>]. However, in vitro studies raise concern about the potential selection of resistant mutants during treatment with fluoroquinolones [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/99,100\" class=\"abstract_t\">99,100</a>]. Although data suggest that <a href=\"topic.htm?path=moxifloxacin-drug-information\" class=\"drug drug_general\">moxifloxacin</a> may have similar in vitro activity as levofloxacin against <em>S. maltophilia </em>[<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/101\" class=\"abstract_t\">101</a>], there are no Clinical and Laboratory Standards Institute (CLSI) defined breakpoints for moxifloxacin. Therefore, it is our practice to preferentially use levofloxacin rather than moxifloxacin for treatment of <em>S. maltophilia</em> infections.</p><p><a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">Minocycline</a> and <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a> also have low minimal inhibitory concentrations among <em>S. maltophilia</em> isolates [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/92,93,102\" class=\"abstract_t\">92,93,102</a>], and each has been shown in small retrospective studies to be associated with clinical outcomes that are comparable to those with TMP-SMX [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/103,104\" class=\"abstract_t\">103,104</a>]. However, low serum drug levels of tigecycline, which limit its utility for bloodstream infections, and concerns about higher mortality rates associated with tigecycline compared with other agents for pneumonia treatment dampen enthusiasm for this agent.</p><p>Ticarcillin-clavulanic acid had been proposed as an alternate therapeutic agent, although rates of in vitro resistance are reported to be as high as 55 percent [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/18,39,105\" class=\"abstract_t\">18,39,105</a>]. Resistance rates to <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> are also relatively high [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/93\" class=\"abstract_t\">93</a>]. Polymyxins (eg, <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a> sulfate) have variable rates of in vitro activity against <em>S. maltophilia</em>.</p><p>Otherwise, <em>S. maltophilia</em> has high rates of resistance, either through intrinsic or acquired mechanisms, to other beta-lactams, <a href=\"topic.htm?path=aztreonam-drug-information\" class=\"drug drug_general\">aztreonam</a>, aminoglycosides, <a href=\"topic.htm?path=fosfomycin-drug-information\" class=\"drug drug_general\">fosfomycin</a>, and carbapenems. Resistance to carbapenems should be presumed regardless of susceptibility testing results.</p><p>Because of the high rates of resistance to many antibiotic classes, there has been interest in the potential for synergistic activity with combination regimens. Thus far, clinical data regarding benefit of combination therapy are limited, and so its role remains uncertain. In one prospective study of patients with <em>S. maltophilia</em> bacteremia, receipt of two or more of TMP-SMX, a third generation cephalosporin, and an extended-spectrum penicillin was associated with lower mortality rates compared with receipt of just one [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/57\" class=\"abstract_t\">57</a>]. The evidence for combination therapy resides predominantly in in vitro studies. Several have reported in vitro synergy for various combinations of antibiotics including TMP-SMX plus <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, TMP-SMX plus ticarcillin-clavulanic acid, and ticarcillin-clavulanic acid plus <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/106-108\" class=\"abstract_t\">106-108</a>].</p><p class=\"headingAnchor\" id=\"H1457755667\"><span class=\"h2\">Approach to antibiotic selection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TMP-SMX (administered as 15 <span class=\"nowrap\">mg/kg/day</span> of the TMP component in three or four divided doses, adjusted for renal function) is the treatment of choice [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7\" class=\"abstract_t\">7</a>], and we usually use this for empiric (ie, prior to the availability of susceptibility testing results) and directed therapy (if the isolate is susceptible) of <em>S. maltophilia</em> infections. For empiric therapy of <em>S. maltophilia </em>infections in severely ill patients, patients with neutropenia or other immunocompromising condition, and patients with persistent signs and symptoms despite seemingly appropriate therapy, we suggest addition of a second active agent (eg, <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> or <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a> based on local antibiogram and patient factors such as allergies) until susceptibility results are known.</p><p>For patients who cannot use TMP-SMX because of hypersensitivity or other expected drug toxicity, we use <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> or <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>, again based on knowledge of the local antibiogram and patient-specific factors such as allergies <span class=\"nowrap\">and/or</span> need for coverage of additional pathogens, for empiric therapy. If the isolate is susceptible to levofloxacin, it is appropriate to continue levofloxacin as directed therapy of <em>S. maltophilia</em>, particularly if there is a polymicrobial infection and levofloxacin is treating other identified pathogens. If the isolate is susceptible to other beta-lactams (such as <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">ticarcillin-clavulanate</a> or ceftazidime), these are also reasonable alternatives if TMP-SMX cannot be used.</p><p>If the isolate is susceptible to TMP-SMX but not to fluoroquinolones or any beta-lactams, we favor rapid desensitization for patients who have an immunoglobulin E mediated hypersensitivity reaction to TMP-SMX (see <a href=\"topic.htm?path=rapid-drug-desensitization-for-immediate-hypersensitivity-reactions\" class=\"medical medical_review\">&quot;Rapid drug desensitization for immediate hypersensitivity reactions&quot;</a>) [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7,109\" class=\"abstract_t\">7,109</a>]. Otherwise, potential alternatives include <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a>, <a href=\"topic.htm?path=tigecycline-drug-information\" class=\"drug drug_general\">tigecycline</a>, and <a href=\"topic.htm?path=colistin-colistimethate-drug-information\" class=\"drug drug_general\">colistin</a>, each of which are associated with particular adverse effects. Consultation with an expert in infectious diseases is advised.</p><p>Evidence supporting this approach to antimicrobial selection is discussed elsewhere. (See <a href=\"#H3886429437\" class=\"local\">'Efficacy of antibiotic options'</a> above.)</p><p class=\"headingAnchor\" id=\"H826693256\"><span class=\"h2\">Duration of therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The duration of therapy depends on the site of the infection; 14 days of therapy is appropriate for bacteremia and 7 days of therapy is appropriate for hospital-acquired pneumonia in an immunocompetent host, as long as there has been evidence of clinical improvement. Longer durations of therapy (10 to 14 days) are often used in immunocompromised hosts. (See appropriate topic reviews for discussion regarding the duration of therapy for specific infections). </p><p class=\"headingAnchor\" id=\"H390920970\"><span class=\"h2\">Other management issues</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to antimicrobial treatment, certain infections may warrant additional interventions, such as catheter removal or wound debridement. As an example, for catheter-associated blood stream infections, removal of the catheter is important in reducing the rate of relapse [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/86\" class=\"abstract_t\">86</a>]. </p><p class=\"headingAnchor\" id=\"H465013486\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>S. maltophilia</em> infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals. </p><p>Overall, mortality estimates range from 21 to 69 percent [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/58,110,111\" class=\"abstract_t\">58,110,111</a>]. However, the actual mortality attributed to these infections when controlling for other variables is unclear. Retrospective analyses have sought to identify independent risk factors associated with mortality in patients infected with <em>S. maltophilia</em>; in one retrospective cohort study, admission to an intensive care unit and delay in effective treatment were found to be independent risk factors for mortality [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H101330444\"><span class=\"h1\">PREVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Infection control and antibiotic stewardship measures are important to minimize the incidence of <em>S. maltophilia</em> infections and for reducing emergence of resistant strains. These measures include appropriate use of antibiotics, avoidance of prolonged or unnecessary use of foreign devices, and adherence to hand hygiene practices. Strict hand hygiene and contact isolation procedures have been utilized to reduce clonal spread in the intensive care unit setting [<a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/112\" class=\"abstract_t\">112</a>]. (See <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2964717\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Stenotrophomonas maltophilia</em> is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen associated with high morbidity and mortality in severely immunocompromised and debilitated individuals. Risk factors associated with <em>Stenotrophomonas</em> infection include admission to an intensive care unit, HIV infection, malignancy, cystic fibrosis, neutropenia, mechanical ventilation, central venous catheters, recent surgery, trauma, and previous therapy with broad-spectrum antibiotics. (See <a href=\"#H47084650\" class=\"local\">'Microbiology'</a> above and <a href=\"#H47084657\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pneumonia (usually hospital-acquired) and bacteremia (often associated with an indwelling catheter) are the most common manifestations of <em>S. maltophilia</em> infection. Less common manifestations include endocarditis, mastoiditis, peritonitis, meningitis,<sup> </sup>soft tissue infection, wound infection, urinary tract infection, and ocular infection. (See <a href=\"#H2963639\" class=\"local\">'Disease associations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Growth of <em>S. maltophilia</em> from normally sterile sites (such as blood or peritoneal fluid) should be interpreted to represent true infection. In patients with clinical evidence of pneumonia, cultures growing <em>S. maltophilia</em> from respiratory sites should be interpreted to be consistent with infection, but in its absence, <em>S. maltophilia</em> growth probably represents colonization rather than invasive disease. Similarly, interpretation of culture data obtained from non-sterile sites (eg, indwelling catheters or drains) must take into account the organism's propensity to colonize foreign material without causing infection. (See <a href=\"#H2258015482\" class=\"local\">'Diagnosis of infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For empiric and directed therapy of <em>S. maltophilia</em> infections, we suggest <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (TMP-SMX) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). For empiric treatment of patients who are severely ill with <em>S. maltophilia</em> infections, who have an immunocompromising condition, or who have persistent symptoms despite TMP-SMX, we also suggest adding a second agent (such as <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> or <a href=\"topic.htm?path=ceftazidime-drug-information\" class=\"drug drug_general\">ceftazidime</a>) until susceptibility results are available (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If a patient cannot use TMP-SMX because of hypersensitivity or other expected drug toxicity, we use levofloxacin or ceftazidime for empiric therapy; either of these or <a href=\"topic.htm?path=ticarcillin-and-clavulanate-potassium-united-states-not-available-drug-information\" class=\"drug drug_general\">ticarcillin-clavulanate</a> is also an acceptable alternative for directed therapy if the isolate is susceptible. (See <a href=\"#H1457755667\" class=\"local\">'Approach to antibiotic selection'</a> above and <a href=\"#H3886429437\" class=\"local\">'Efficacy of antibiotic options'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The duration of therapy depends on the site of the infection; 14 days of therapy is appropriate for bacteremia and 7 days of therapy is usually appropriate for hospital-acquired pneumonia in an immunocompetent host. Certain infections may warrant additional interventions, such as catheter removal or wound debridement. (See <a href=\"#H826693256\" class=\"local\">'Duration of therapy'</a> above and <a href=\"#H390920970\" class=\"local\">'Other management issues'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection control measures are important to minimize the incidence of <em>S. maltophilia</em> infections and for reducing emergence of resistant strains. These measures include judicious use of antibiotics, avoidance of prolonged or unnecessary use of foreign devices, and adherence to hand hygiene practices. (See <a href=\"#H101330444\" class=\"local\">'Prevention'</a> above and <a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">&quot;Infection prevention: Precautions for preventing transmission of infection&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/1\" class=\"nounderline abstract_t\">Paez JI, Tengan FM, Barone AA, et al. Factors associated with mortality in patients with bloodstream infection and pneumonia due to Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2008; 27:901.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/2\" class=\"nounderline abstract_t\">Kwa AL, Low JG, Lim TP, et al. Independent predictors for mortality in patients with positive Stenotrophomonas maltophilia cultures. Ann Acad Med Singapore 2008; 37:826.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/3\" class=\"nounderline abstract_t\">Lai CH, Chi CY, Chen HP, et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infect 2004; 37:350.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/4\" class=\"nounderline abstract_t\">Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11:57.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/5\" class=\"nounderline abstract_t\">Calza L, Manfredi R, Chiodo F. Stenotrophomonas (Xanthomonas) maltophilia as an emerging opportunistic pathogen in association with HIV infection: a 10-year surveillance study. Infection 2003; 31:155.</a></li><li class=\"breakAll\">Giligan P, Lum G, Vandamme PAR, Whittier S. Burkholderia, Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea, and Acidovorax. In: Manual of Clinical Microbiology, 8th, Murray PR (Ed), ASM, Washington 2003.</li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/7\" class=\"nounderline abstract_t\">Looney WJ, Narita M, M&uuml;hlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9:312.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/8\" class=\"nounderline abstract_t\">Crossman LC, Gould VC, Dow JM, et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol 2008; 9:R74.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/9\" class=\"nounderline abstract_t\">Elsner HA, D&uuml;hrsen U, Hollwitz B, et al. Fatal pulmonary hemorrhage in patients with acute leukemia and fulminant pneumonia caused by Stenotrophomonas maltophilia. Ann Hematol 1997; 74:155.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/10\" class=\"nounderline abstract_t\">Ganadu M, Mura GL, Campus AM, et al. Relapsing pyrogenic reactions due to Xanthomonas maltophilia in a dialysis patient with a long-term central venous catheter. Nephrol Dial Transplant 1996; 11:197.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/11\" class=\"nounderline abstract_t\">Girijaratnakumari T, Raja A, Ramani R, et al. Meningitis due to Xanthomonas maltophilia. J Postgrad Med 1993; 39:153.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/12\" class=\"nounderline abstract_t\">Lo WT, Wang CC, Lee CM, Chu ML. Successful treatment of multi-resistant Stenotrophomonas maltophilia meningitis with ciprofloxacin in a pre-term infant. Eur J Pediatr 2002; 161:680.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/13\" class=\"nounderline abstract_t\">Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia: an unusual cause of biliary sepsis. Clin Infect Dis 1995; 21:1032.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/14\" class=\"nounderline abstract_t\">Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Septic prepatellar bursitis caused by Stenotrophomonas (Xanthomonas) maltophilia. Clin Infect Dis 1996; 22:388.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/15\" class=\"nounderline abstract_t\">Smeets JG, L&ouml;we SH, Veraart JC. Cutaneous infections with Stenotrophomonas maltophilia in patients using immunosuppressive medication. J Eur Acad Dermatol Venereol 2007; 21:1298.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/16\" class=\"nounderline abstract_t\">Gilardi GL. Infrequently encountered Pseudomonas species causing infection in humans. Ann Intern Med 1972; 77:211.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/17\" class=\"nounderline abstract_t\">Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990; 12:997.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/18\" class=\"nounderline abstract_t\">Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007; 26:229.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/19\" class=\"nounderline abstract_t\">Gilardi GL. Pseudomonas maltophilia infections in man. Am J Clin Pathol 1969; 51:58.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/20\" class=\"nounderline abstract_t\">Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990; 11:134.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/21\" class=\"nounderline abstract_t\">Falagas ME, Kastoris AC, Vouloumanou EK, et al. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009; 4:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/22\" class=\"nounderline abstract_t\">Bottone EJ, Reitano M, Janda JM, et al. Pseudomonas maltophilia exoenzyme activity as correlate in pathogenesis of ecthyma gangrenosum. J Clin Microbiol 1986; 24:995.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/23\" class=\"nounderline abstract_t\">Jucker BA, Harms H, Zehnder AJ. Adhesion of the positively charged bacterium Stenotrophomonas (Xanthomonas) maltophilia 70401 to glass and Teflon. J Bacteriol 1996; 178:5472.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/24\" class=\"nounderline abstract_t\">de Oliveira-Garcia D, Dall'Agnol M, Rosales M, et al. Fimbriae and adherence of Stenotrophomonas maltophilia to epithelial cells and to abiotic surfaces. Cell Microbiol 2003; 5:625.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/25\" class=\"nounderline abstract_t\">Di Bonaventura G, Spedicato I, D'Antonio D, et al. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. Antimicrob Agents Chemother 2004; 48:151.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/26\" class=\"nounderline abstract_t\">Mart&iacute;nez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15:647.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/27\" class=\"nounderline abstract_t\">de Oliveira-Garcia D, Dall'Agnol M, Rosales M, et al. Characterization of flagella produced by clinical strains of Stenotrophomonas maltophilia. Emerg Infect Dis 2002; 8:918.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/28\" class=\"nounderline abstract_t\">Waters VJ, G&oacute;mez MI, Soong G, et al. Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia. Infect Immun 2007; 75:1698.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/29\" class=\"nounderline abstract_t\">Avison MB, Higgins CS, von Heldreich CJ, et al. Plasmid location and molecular heterogeneity of the L1 and L2 beta-lactamase genes of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:413.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/30\" class=\"nounderline abstract_t\">Crowder MW, Walsh TR, Banovic L, et al. Overexpression, purification, and characterization of the cloned metallo-beta-lactamase L1 from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1998; 42:921.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/31\" class=\"nounderline abstract_t\">Saino Y, Inoue M, Mitsuhashi S. Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873. Antimicrob Agents Chemother 1984; 25:362.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/32\" class=\"nounderline abstract_t\">Walsh TR, MacGowan AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41:1460.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/33\" class=\"nounderline abstract_t\">Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomonas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995; 30 Suppl:453.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/34\" class=\"nounderline abstract_t\">Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27 Suppl 1:S93.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/35\" class=\"nounderline abstract_t\">Lambert T, Ploy MC, Denis F, Courvalin P. Characterization of the chromosomal aac(6')-Iz gene of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1999; 43:2366.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/36\" class=\"nounderline abstract_t\">Li XZ, Zhang L, McKay GA, Poole K. Role of the acetyltransferase AAC(6')-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother 2003; 51:803.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/37\" class=\"nounderline abstract_t\">Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr Pharm Biotechnol 2002; 3:77.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/38\" class=\"nounderline abstract_t\">Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis 2007; 45:1602.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/39\" class=\"nounderline abstract_t\">Falagas ME, Valkimadi PE, Huang YT, et al. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008; 62:889.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/40\" class=\"nounderline abstract_t\">Wheat PF, Winstanley TG, Spencer RC. Effect of temperature on antimicrobial susceptibilities of Pseudomonas maltophilia. J Clin Pathol 1985; 38:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/41\" class=\"nounderline abstract_t\">Rahmati-Bahram A, Magee JT, Jackson SK. Growth temperature-dependent variation of cell envelope lipids and antibiotic susceptibility in Stenotrophomonas (Xanthomonas) maltophilia. J Antimicrob Chemother 1995; 36:317.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/42\" class=\"nounderline abstract_t\">Rahmati-Bahram A, Magee JT, Jackson SK. Temperature-dependent aminoglycoside resistance in Stenotrophomonas (Xanthomonas) maltophilia; alterations in protein and lipopolysaccharide with growth temperature. J Antimicrob Chemother 1996; 37:665.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/43\" class=\"nounderline abstract_t\">Rahmati-Bahram A, Magee JT, Jackson SK. Effect of temperature on aminoglycoside binding sites in Stenotrophomonas maltophilia. J Antimicrob Chemother 1997; 39:19.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/44\" class=\"nounderline abstract_t\">Alonso A, Mart&iacute;nez JL. Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2000; 44:3079.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/45\" class=\"nounderline abstract_t\">Alonso A, Martinez JL. Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45:1879.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/46\" class=\"nounderline abstract_t\">Zhang L, Li XZ, Poole K. Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. J Antimicrob Chemother 2001; 48:549.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/47\" class=\"nounderline abstract_t\">Alonso A, Sanchez P, Mart&iacute;nez JL. Stenotrophomonas maltophilia D457R contains a cluster of genes from gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob Agents Chemother 2000; 44:1778.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/48\" class=\"nounderline abstract_t\">del Toro MD, Rodr&iacute;guez-Bano J, Herrero M, et al. Clinical epidemiology of Stenotrophomonas maltophilia colonization and infection: a multicenter study. Medicine (Baltimore) 2002; 81:228.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/49\" class=\"nounderline abstract_t\">Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 2006; 5:23.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/50\" class=\"nounderline abstract_t\">K&ouml;seo&#287;lu O, Sener B, G&uuml;lmez D, et al. Stenotrophomonas maltophilia as a nosocomial pathogen. New Microbiol 2004; 27:273.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/51\" class=\"nounderline abstract_t\">Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 1994; 38:2317.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/52\" class=\"nounderline abstract_t\">Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H. In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2002; 46:3997.</a></li><li class=\"breakAll\">Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Eighteenth informational supplement [Document M100-S18]. Wayne, PA 2008.</li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/54\" class=\"nounderline abstract_t\">Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54:2735.</a></li><li class=\"breakAll\">The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. http://www.eucast.org (Accessed on December 02, 2016).</li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/56\" class=\"nounderline abstract_t\">Morrison AJ Jr, Hoffmann KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986; 24:52.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/57\" class=\"nounderline abstract_t\">Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996; 22:508.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/58\" class=\"nounderline abstract_t\">Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect 2008; 70:101.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/59\" class=\"nounderline abstract_t\">Victor MA, Arpi M, Bruun B, et al. Xanthomonas maltophilia bacteremia in immunocompromised hematological patients. Scand J Infect Dis 1994; 26:163.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/60\" class=\"nounderline abstract_t\">Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 1997; 24:1131.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/61\" class=\"nounderline abstract_t\">Falagas ME, Kastoris AC, Vouloumanou EK, Dimopoulos G. Community-acquired Stenotrophomonas maltophilia infections: a systematic review. Eur J Clin Microbiol Infect Dis 2009; 28:719.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/62\" class=\"nounderline abstract_t\">Guyot A, Turton JF, Garner D. Outbreak of Stenotrophomonas maltophilia on an intensive care unit. J Hosp Infect 2013; 85:303.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/63\" class=\"nounderline abstract_t\">Alfieri N, Ramotar K, Armstrong P, et al. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing. Infect Control Hosp Epidemiol 1999; 20:553.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/64\" class=\"nounderline abstract_t\">Weber DJ, Rutala WA, Blanchet CN, et al. Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia. Am J Infect Control 1999; 27:59.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/65\" class=\"nounderline abstract_t\">Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogenic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis 2000; 30:195.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/66\" class=\"nounderline abstract_t\">Sakhnini E, Weissmann A, Oren I. Fulminant Stenotrophomonas maltophilia soft tissue infection in immunocompromised patients: an outbreak transmitted via tap water. Am J Med Sci 2002; 323:269.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/67\" class=\"nounderline abstract_t\">Hench C, Johnson N, Reyes V, et al. Outbreak of Stenotrophomonas maltophilia bloodstream infections in an outpatient dialysis center. Am J Infect Control 2007; 35:E130.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/68\" class=\"nounderline abstract_t\">Verweij PE, Meis JF, Christmann V, et al. Nosocomial outbreak of colonization and infection with Stenotrophomonas maltophilia in preterm infants associated with contaminated tap water. Epidemiol Infect 1998; 120:251.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/69\" class=\"nounderline abstract_t\">&Ccedil;etin BS, &Ccedil;elebi S, &Ouml;zkan H, et al. Stenotrophomonas maltophilia outbreak in neonatal intensive care unit and outbreak management. J Pediatr Inf 2015; 9:147.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/70\" class=\"nounderline abstract_t\">Wang C, Hsu S, Tsai T, Wang N. An outbreak of trimethoprim/sulfamethoxazole-resistant Stenotrophomonas maltophilia meningitis associated with neuroendoscopy. J Med Sci 2014; 34:235.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/71\" class=\"nounderline abstract_t\">Guy M, Vanhems P, Dananch&eacute; C, et al. Outbreak of pulmonary Pseudomonas&nbsp;aeruginosa and Stenotrophomonas&nbsp;maltophilia infections related to contaminated bronchoscope suction valves, Lyon, France, 2014. Euro Surveill 2016; 21.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/72\" class=\"nounderline abstract_t\">Ece G, Erac B, Limoncu MH, et al. Stenotrophomonas maltophilia Pseudo-outbreak at a University Hospital Bronchoscopy Unit in Turkey. West Indian Med J 2014; 63:59.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/73\" class=\"nounderline abstract_t\">Waite TD, Georgiou A, Abrishami M, Beck CR. Pseudo-outbreaks of Stenotrophomonas maltophilia on an intensive care unit in England. J Hosp Infect 2016; 92:392.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/74\" class=\"nounderline abstract_t\">Botana-Rial M, Leiro-Fern&aacute;ndez V, N&uacute;&ntilde;ez-Delgado M, et al. A Pseudo-Outbreak of Pseudomonas putida and Stenotrophomonas maltophilia in a Bronchoscopy Unit. Respiration 2016; 92:274.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/75\" class=\"nounderline abstract_t\">Gales AC, Jones RN, Forward KR, et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001; 32 Suppl 2:S104.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/76\" class=\"nounderline abstract_t\">Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31:705.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/77\" class=\"nounderline abstract_t\">Chen YF, Chung PC, Hsiao CH. Stenotrophomonas maltophilia keratitis and scleritis. Chang Gung Med J 2005; 28:142.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/78\" class=\"nounderline abstract_t\">Penland RL, Wilhelmus KR. Stenotrophomonas maltophilia ocular infections. Arch Ophthalmol 1996; 114:433.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/79\" class=\"nounderline abstract_t\">Saugel B, Eschermann K, Hoffmann R, et al. Stenotrophomonas maltophilia in the respiratory tract of medical intensive care unit patients. Eur J Clin Microbiol Infect Dis 2012; 31:1419.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/80\" class=\"nounderline abstract_t\">Araoka H, Fujii T, Izutsu K, et al. Rapidly progressive fatal hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in hematologic malignancy. Transpl Infect Dis 2012; 14:355.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/81\" class=\"nounderline abstract_t\">Tada K, Kurosawa S, Hiramoto N, et al. Stenotrophomonas maltophilia infection in hematopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant 2013; 48:74.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/82\" class=\"nounderline abstract_t\">Salsgiver EL, Fink AK, Knapp EA, et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 2016; 149:390.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/83\" class=\"nounderline abstract_t\">Stanojevic S, Ratjen F, Stephens D, et al. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. J Cyst Fibros 2013; 12:575.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/84\" class=\"nounderline abstract_t\">Cogen J, Emerson J, Sanders DB, et al. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015; 50:763.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/85\" class=\"nounderline abstract_t\">Boktour M, Hanna H, Ansari S, et al. Central venous catheter and Stenotrophomonas maltophilia bacteremia in cancer patients. Cancer 2006; 106:1967.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/86\" class=\"nounderline abstract_t\">Lai CH, Wong WW, Chin C, et al. Central venous catheter-related Stenotrophomonas maltophilia bacteraemia and associated relapsing bacteraemia in haematology and oncology patients. Clin Microbiol Infect 2006; 12:986.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/87\" class=\"nounderline abstract_t\">Apisarnthanarak A, Mayfield JL, Garison T, et al. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol 2003; 24:269.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/88\" class=\"nounderline abstract_t\">Wu AL, Yeh LK, Ma DH, et al. Clinical Characteristics of Stenotrophomonas maltophilia Keratitis. Cornea 2016; 35:795.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/89\" class=\"nounderline abstract_t\">Teo WY, Chan MY, Lam CM, Chong CY. Skin manifestation of Stenotrophomonas maltophilia infection--a case report and review article. Ann Acad Med Singapore 2006; 35:897.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/90\" class=\"nounderline abstract_t\">Son YM, Na SY, Lee HY, et al. Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient. Ann Dermatol 2009; 21:389.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/91\" class=\"nounderline abstract_t\">Pathmanathan A, Waterer GW. Significance of positive Stenotrophomonas maltophilia culture in acute respiratory tract infection. Eur Respir J 2005; 25:911.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/92\" class=\"nounderline abstract_t\">Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014; 43:328.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/93\" class=\"nounderline abstract_t\">Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6:893.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/94\" class=\"nounderline abstract_t\">Cho SY, Lee DG, Choi SM, et al. Stenotrophomonas maltophilia bloodstream infection in patients with hematologic malignancies: a retrospective study and in vitro activities of antimicrobial combinations. BMC Infect Dis 2015; 15:69.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/95\" class=\"nounderline abstract_t\">Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother 2014; 58:176.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/96\" class=\"nounderline abstract_t\">Tsiodras S, Pittet D, Carmeli Y, et al. Clinical implications of stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000; 32:651.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/97\" class=\"nounderline abstract_t\">Wang CH, Lin JC, Lin HA, et al. Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study. J Microbiol Immunol Infect 2016; 49:378.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/98\" class=\"nounderline abstract_t\">Cho SY, Kang CI, Kim J, et al. Can levofloxacin be a useful alternative to trimethoprim-sulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother 2014; 58:581.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/99\" class=\"nounderline abstract_t\">Ba BB, Feghali H, Arpin C, et al. Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model. Antimicrob Agents Chemother 2004; 48:946.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/100\" class=\"nounderline abstract_t\">Garrison MW, Anderson DE, Campbell DM, et al. Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model. Antimicrob Agents Chemother 1996; 40:2859.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/101\" class=\"nounderline abstract_t\">Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother 2008; 20:38.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/102\" class=\"nounderline abstract_t\">G&oacute;mez-Garc&eacute;s JL, Aracil B, Gil Y, Burillo A. Susceptibility of 228 non-fermenting gram-negative rods to tigecycline and six other antimicrobial drugs. J Chemother 2009; 21:267.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/103\" class=\"nounderline abstract_t\">Tek&ccedil;e YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 2012; 24:150.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/104\" class=\"nounderline abstract_t\">Hand E, Davis H, Kim T, Duhon B. Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. J Antimicrob Chemother 2016; 71:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/105\" class=\"nounderline abstract_t\">Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005; 25:95.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/106\" class=\"nounderline abstract_t\">G&uuml;lmez D, Cakar A, Sener B, et al. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 2010; 16:322.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/107\" class=\"nounderline abstract_t\">Liaw SJ, Teng LJ, Hsueh PR, et al. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 2002; 101:495.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/108\" class=\"nounderline abstract_t\">Poulos CD, Matsumura SO, Willey BM, et al. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 1995; 39:2220.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/109\" class=\"nounderline abstract_t\">Yilmaz M, Celik AF, Mert A. Successfully treated nosocomial Stenotrophomonas maltophilia bacteremia following desensitization to trimethoprim-sulfamethoxazole. J Infect Chemother 2007; 13:122.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/110\" class=\"nounderline abstract_t\">Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002; 34:1653.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/111\" class=\"nounderline abstract_t\">Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004; 37:359.</a></li><li><a href=\"https://www.uptodate.com/contents/stenotrophomonas-maltophilia/abstract/112\" class=\"nounderline abstract_t\">Barchitta M, Cipresso R, Giaquinta L, et al. Acquisition and spread of Acinetobacter baumannii and Stenotrophomonas maltophilia in intensive care patients. Int J Hyg Environ Health 2009; 212:330.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 13961 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2964717\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H47084643\" id=\"outline-link-H47084643\">INTRODUCTION</a></li><li><a href=\"#H47084650\" id=\"outline-link-H47084650\">MICROBIOLOGY</a></li><li><a href=\"#H47084657\" id=\"outline-link-H47084657\">EPIDEMIOLOGY</a></li><li><a href=\"#H2963639\" id=\"outline-link-H2963639\">DISEASE ASSOCIATIONS</a><ul><li><a href=\"#H4108514156\" id=\"outline-link-H4108514156\">Pulmonary infection</a></li><li><a href=\"#H1196897287\" id=\"outline-link-H1196897287\">Bacteremia</a></li><li><a href=\"#H131225346\" id=\"outline-link-H131225346\">Other manifestations</a></li></ul></li><li><a href=\"#H2258015482\" id=\"outline-link-H2258015482\">DIAGNOSIS OF INFECTION</a></li><li><a href=\"#H1439026460\" id=\"outline-link-H1439026460\">TREATMENT</a><ul><li><a href=\"#H1646623428\" id=\"outline-link-H1646623428\">Indications</a></li><li><a href=\"#H3886429437\" id=\"outline-link-H3886429437\">Efficacy of antibiotic options</a></li><li><a href=\"#H1457755667\" id=\"outline-link-H1457755667\">Approach to antibiotic selection</a></li><li><a href=\"#H826693256\" id=\"outline-link-H826693256\">Duration of therapy</a></li><li><a href=\"#H390920970\" id=\"outline-link-H390920970\">Other management issues</a></li></ul></li><li><a href=\"#H465013486\" id=\"outline-link-H465013486\">PROGNOSIS</a></li><li><a href=\"#H101330444\" id=\"outline-link-H101330444\">PREVENTION</a></li><li><a href=\"#H2964717\" id=\"outline-link-H2964717\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cystic-fibrosis-antibiotic-therapy-for-chronic-pulmonary-infection\" class=\"medical medical_review\">Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=gram-negative-bacillary-bacteremia-in-adults\" class=\"medical medical_review\">Gram-negative bacillary bacteremia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infection-prevention-precautions-for-preventing-transmission-of-infection\" class=\"medical medical_review\">Infection prevention: Precautions for preventing transmission of infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rapid-drug-desensitization-for-immediate-hypersensitivity-reactions\" class=\"medical medical_review\">Rapid drug desensitization for immediate hypersensitivity reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-hospital-acquired-and-ventilator-associated-pneumonia-in-adults\" class=\"medical medical_review\">Treatment of hospital-acquired and ventilator-associated pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-intravascular-catheter-related-infections\" class=\"medical medical_review\">Treatment of intravascular catheter-related infections</a></li></ul></div></div>","javascript":null}